Format

Send to

Choose Destination
See comment in PubMed Commons below
Pediatr Gastroenterol Hepatol Nutr. 2013 Jun;16(2):65-70. doi: 10.5223/pghn.2013.16.2.65. Epub 2013 Jun 30.

Monitoring and safety of azathioprine therapy in inflammatory bowel disease.

Author information

  • 1Department of Pediatrics, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.

Abstract

Azathioprine is the most common drug used to maintain clinical remission in inflammatory bowel disease. This drug is also important as a steroid-sparing agent in steroid-dependent and chronically active inflammatory bowel disease. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine. The dose of azathioprine has to be reduced or the therapy has to be discontinued frequently because of drug-induced toxicity. In this review, we discuss monitoring of thiopurines, adverse events, malignant complications and how to use azathioprine safely and usefully.

KEYWORDS:

Azathioprine; Inflammatory bowel diseases

Publication Types

Publication Types

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition Icon for PubMed Central
    Loading ...
    Write to the Help Desk